Article Sidebar
Views PDF: 250
EVALUATING THE EFFECTIVENESS OF GEMOX REGIMEN IN THE TREATMENT OF PANCREATIC CARCINOMA AT HANOI MEDICAL UNIVERSITY HOSPITAL
Main Article Content
Abstract
Objectives: To evaluate the treatment results of GEMOX regimen on locally advanced and metastastic pancreatic cancer. Patients and methods: Descriptive retrospective study on 33 unresectable pancreatic cancer patients treated at National Cancer Hospital from January 2016 to July 2021. Results: The age group 41-60 was the most common group (51,5%). Most patients were male (66.7%). The total number of treatment cycle was 230 with the average number of cycles each patient was 7. Six patients had partial response (18,2%), and five patients had stable disease (15,1%). CA 19-9 serum level tends to decrease in patients with response or stable disease (p<0.05). Anemia was the most common adverse event (69.6%), followed by thrombocytopenia (37,0%), most of which were in grade 1,2. No grade 3,4 toxicity on liver or kidney was observed. Conclusion: GEMOX regimen was safe and effective in a number of patients with unresectable pancreatic cancer.
Article Details
Keywords
pancreatic cancer, GEMOX
References
2. Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
3. Siegel R., Naishadham D., and Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin, 63(1), 11–30.
4.Genkinger J.M., Spiegelman D., Anderson K.E. et al. (2009). Alcohol Intake And Pancreatic Cancer Risk: A Pooled Analysis of Fourteen Cohort Studies. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol, 18(3), 765–776.
5. Louvet C., Labianca R., Hammel P., et al. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol Off J Am Soc Clin Oncol, 23(15), 3509–3516.
6. Đặng Thị Vân Anh (2012). Đánh giá kết quả điều trị hoá trị ung thư biểu mô tuyến tuỵ giai đoạn tiến triển di căn. Luận văn Bác sỹ nội trú. Đại học Y Hà Nội.
7. Louvet C., André T., Lledo G., et al. (2002). Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol Off J Am Soc Clin Oncol, 20(6), 1512–1518.